The influence of statins on the expansion rate and rupture risk of abdominal aortic aneurysms.
Abdominal aortic aneurysms (AAA) have a prevalence between 1.3-8.9% in men and 1.0-2.2% in women aged above 55 years. Furthermore, AAA cause 1-3% of all deaths among men aged 65-85 years in developed countries. As the disorder is invariably associated with severe atherosclerotic damage of the arterial wall, it has traditionally been regarded as a direct consequence of generalized atherosclerotic disease. In patients with occlusive aortic disease, dyslipidemia is a well established risk factor. However, in patients with aneursymatic aortic disease, the association between dyslipidemia and the development of AAA is less clear. Large clinical trials in patients with cardiac and peripheral arterial disease have shown the strong relation between dyslipidemia, statin therapy and the risk of cardiovascular disease. Importantly, the effects of statin therapy were still present irrespective of the decrease in serum cholesterol levels. These findings resulted in the discussion of potential non-lipid lowering effects of statin therapy. These ''pleiotropic effects'' compose a diversity of cellular events which have an effect on several components of the arterial wall, including: 1) endothelial cells; 2) smooth muscle cells; 3) platelets; 4) monocytes/macrophages; and 5) the process of inflammation. In the general population the role of dyslipidemia as an independent risk factor for AAA is debated. However, as patients with AAA frequently have concomitant arterial disease, statin therapy is often recommended. As a result, the non-lipid lowering effects of statins on aneurysm expansion rate are hardly studied, and most evidence comes from experimental and animal studies. In the current review article we provide an overview of all available literature on the effects of dyslipidemia, statin therapy and the risk of AAA expansion and rupture. In the first part we summarize all population-based studies that investigated the relation between hypercholesterolemia and the development of AAA. In the second part, the available literature regarding the effects of statins on aneurysm growth, expansion rate and the risk of rupture is summarized, including in vitro, animal and clinical human studies.
VAN KUIJK
J P
JP
Department of Vascular Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.
FLU
W J
WJ
WITTEVEEN
O P
OP
VOUTE
M
M
BAX
J J
JJ
POLDERMANS
D
D
D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D017544:Aortic Aneurysm, Abdominal / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D001019:Aortic Rupture / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D018450:Disease Progression; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors